ASCO 2026 | Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky, MD, MS, Emory University, Atlanta, GA, discusses the clinical relevance of progression-free survival after next line of treatment (PFS2) in triple-negative breast cancer (TNBC). While PFS2 analysis has limitations, such as the lack of control over scan frequency and blinded independent central review, the majority of patients in the control arm in the ASCENT-04 trial (NCT05382286) received sacituzumab govitecan monotherapy SG, which was also provided to most patients on the study. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There is a clinical relevance of PFS2 in this particular subtype of breast cancer. It’s important to note that in real-world data, even about 50% of patients don’t go on to get second-line therapy. This is a disease type where we just don’t quite have as many options as, say, estrogen-driven or HER2-positive breast cancer. There are limitations in a PFS2 analysis, including after patients had tumors that had progressed after their first-line therapy, it wasn’t controlled for how frequently the scans were being done, and there wasn’t a blinded independent central review on that subsequent progression as compared to the first...
There is a clinical relevance of PFS2 in this particular subtype of breast cancer. It’s important to note that in real-world data, even about 50% of patients don’t go on to get second-line therapy. This is a disease type where we just don’t quite have as many options as, say, estrogen-driven or HER2-positive breast cancer. There are limitations in a PFS2 analysis, including after patients had tumors that had progressed after their first-line therapy, it wasn’t controlled for how frequently the scans were being done, and there wasn’t a blinded independent central review on that subsequent progression as compared to the first. But it is also worth noting that 80% of patients in the control arm went on to get monotherapy SG and that the SG was provided for the majority of those patients on the study. Only about 15 participants received that as standard of care.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
